Connective Tissue Disease associated with Interstitial Lung Disease Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Connective Tissue Disease associated with Interstitial Lung Disease market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Boehringer Ingelheim, Roche/Genentech, Bristol Myers Squibb, Novartis, Pfizer, Gilead Sciences, GlaxoSmithKline, AstraZeneca, Johnson & Johnson, Merck & Co., Sanofi, Eli Lilly and Company, AbbVie, Celgene (now part of Bristol Myers Squibb), Vertex Pharmaceuticals, Biogen, Amgen, Takeda Pharmaceutical Company, Daiichi Sankyo, Astellas Pharma

[Nevada, United States] - DelveInsight's "Connective Tissue Disease associated with Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Connective Tissue Disease associated with Interstitial Lung Disease, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Connective Tissue Disease associated with Interstitial Lung Disease Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/connective-tissue-disease-associated-with-interstitial-lung-disease-ctd-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Connective Tissue Disease associated with Interstitial Lung Disease Market Report:
• The Connective Tissue Disease associated with Interstitial Lung Disease market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
• In October, 2024: Prometheus Biosciences, Inc. announced a Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-7240/PRA023 in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD)
• In September, 2024: Genentech, Inc. annouced that the main purpose of their study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
• In August, 2024: GlaxoSmithKline announced that their study ill assess whether treatment of CTD-ILD participants with belimumab in addition to standard therapy will result in the stabilization and/or improvement of lung function and improve symptoms associated with ILD with an acceptable safety profile.
• In the assessment done by DelveInsight, the estimated total prevalent cases of Interstitial Lung Disease (ILD) in the 7MM were ~1,662 thousand in 2023.
• The highest total diagnosed prevalent cases of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) were accounted for by US in 2023 (~132 thousand), which are expected to show a rise in the future.
• Among the European countries, the UK had the highest diagnosed prevalent cases of CTD-ILD with ~27 thousand cases, followed by Germany, which had a prevalent population of 25 thousand in 2023. On the other hand, Spain had the lowest prevalent population (~11 thousand cases).
• Key Connective Tissue Disease associated with Interstitial Lung Disease Companies are as follows: Boehringer Ingelheim, Roche/Genentech, Bristol Myers Squibb, Novartis, Pfizer, Gilead Sciences, GlaxoSmithKline, AstraZeneca, Johnson & Johnson, Merck & Co., Sanofi, Eli Lilly and Company, AbbVie, Celgene (now part of Bristol Myers Squibb), Vertex Pharmaceuticals, Biogen, Amgen, Takeda Pharmaceutical Company, Daiichi Sankyo, Astellas Pharma
• Key Connective Tissue Disease associated with Interstitial Lung Disease Therapies are as follow: OFEV, Belimumab, GSK1550188 (BENLYSTA), Belimumab, bosentan, Tulisokibarts, Vixarelimab, Nintedanib, Interleukin
• Launching multiple stage Connective Tissue Disease associated with Interstitial Lung Disease pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Connective Tissue Disease associated with Interstitial Lung Disease market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/connective-tissue-disease-associated-with-interstitial-lung-disease-ctd-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Connective Tissue Disease associated with Interstitial Lung Disease Overview:
Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD) refers to a group of lung disorders that occur in individuals with connective tissue diseases, such as rheumatoid arthritis (RA), systemic sclerosis (scleroderma), polymyositis/dermatomyositis, Sjogren's syndrome, and lupus. In these cases, the immune system mistakenly attacks the lungs, causing inflammation and scarring (fibrosis) of the interstitial tissue, which impairs the lungs' ability to function properly.

Connective Tissue Disease associated with Interstitial Lung Disease Epidemiology Segmentation:
The Connective Tissue Disease associated with Interstitial Lung Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Connective Tissue Disease associated with Interstitial Lung Disease Total Prevalence
• Connective Tissue Disease associated with Interstitial Lung Disease Prevalent Cases by severity
• Connective Tissue Disease associated with Interstitial Lung Disease Gender-specific Prevalence
• Connective Tissue Disease associated with Interstitial Lung Disease Diagnosed Cases of Episodic and Chronic

For more information about Connective Tissue Disease associated with Interstitial Lung Disease companies working in the treatment market, visit https://www.delveinsight.com/sample-request/connective-tissue-disease-associated-with-interstitial-lung-disease-ctd-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Connective Tissue Disease associated with Interstitial Lung Disease Market Insights
• The CTD-ILD market was valued at approximately USD 1 billion in 2023 and is expected to grow at a CAGR of 8-10% from 2023 to 2030. This growth is driven by increased diagnosis, drug approvals, and better management of connective tissue diseases.
• Major pharmaceutical companies involved in the CTD-ILD market include Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Pfizer, and GlaxoSmithKline, all focusing on developing drugs that target fibrotic processes and immune modulation.
• North America and Europe hold a significant market share due to the higher prevalence of CTDs, well-established healthcare infrastructure, and greater access to advanced treatments.
• However, the Asia-Pacific region is expected to witness rapid growth due to improved healthcare facilities and increasing awareness of the condition.

Connective Tissue Disease associated with Interstitial Lung Disease Drugs Uptake
• Nintedanib has become the first-line therapy for SSc-ILD and is being explored for use in other forms of CTD-ILD, including RA-ILD. Its uptake has been strong due to its demonstrated ability to slow lung function decline.
• Pirfenidone is another antifibrotic drug approved for the treatment of idiopathic pulmonary fibrosis (IPF) and is being investigated for use in other forms of fibrotic ILDs, including CTD-ILD.
• Immunosuppressants remain a cornerstone in managing CTD-ILD, particularly in patients with more inflammatory presentations, such as RA-ILD and lupus-related ILD. However, the efficacy in slowing long-term lung fibrosis is limited compared to antifibrotic therapies.
• Though primarily used for rheumatoid arthritis and certain cancers, rituximab is being increasingly prescribed off-label for CTD-ILD with promising results in managing inflammation and improving lung function.
• Lenabasum is still in clinical trials but has generated interest due to its potential as a disease-modifying treatment for SSc-ILD, with fewer side effects compared to conventional immunosuppressants.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/connective-tissue-disease-associated-with-interstitial-lung-disease-ctd-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Connective Tissue Disease associated with Interstitial Lung Disease Therapies and Key Companies:
• OFEV: Boehringer Ingelheim Pharmaceuticals, Inc.
• Belimumab, GSK1550188 (BENLYSTA): GlaxoSmithKline plc.
• Belimumab: GlaxoSmithKline
• bosentan: Actelion
• Tulisokibart: Prometheus Biosciences
• Vixarelimab: Genentech, Inc.
• Nintedanib: Boehringer Ingelheim
• Interleukin: Assistance Publique

Connective Tissue Disease associated with Interstitial Lung Disease Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Connective Tissue Disease associated with Interstitial Lung Disease.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/connective-tissue-disease-associated-with-interstitial-lung-disease-ctd-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Connective Tissue Disease associated with Interstitial Lung Disease Market Drivers:
• Increasing Prevalence of Connective Tissue Diseases
• Introduction of Antifibrotic Therapies
• Advances in Diagnostic Tools
• Increased Research and Clinical Trials

Connective Tissue Disease associated with Interstitial Lung Disease Market Barriers:
• Rising Awareness of CTD-ILD
• Limited Treatment Options
• Diagnostic Challenges and Delayed Diagnosis
• Regulatory and Reimbursement Hurdles

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/connective-tissue-disease-associated-with-interstitial-lung-disease-ctd-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Connective Tissue Disease associated with Interstitial Lung Disease Market Report:
• Study Period: 2020-2034
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Connective Tissue Disease associated with Interstitial Lung Disease Companies: Boehringer Ingelheim, Roche/Genentech, Bristol Myers Squibb, Novartis, Pfizer, Gilead Sciences, GlaxoSmithKline, AstraZeneca, Johnson & Johnson, Merck & Co., Sanofi, Eli Lilly and Company, AbbVie, Celgene (now part of Bristol Myers Squibb), Vertex Pharmaceuticals, Biogen, Amgen, Takeda Pharmaceutical Company, Daiichi Sankyo, Astellas Pharma
• Key Connective Tissue Disease associated with Interstitial Lung Disease Therapies: OFEV, Belimumab, GSK1550188 (BENLYSTA), Belimumab, bosentan, Tulisokibarts, Vixarelimab, Nintedanib, Interleukin
• Connective Tissue Disease associated with Interstitial Lung Disease Therapeutic Assessment: Current marketed and emerging therapies
• Connective Tissue Disease associated with Interstitial Lung Disease Market Dynamics: Connective Tissue Disease associated with Interstitial Lung Disease Market drivers and Connective Tissue Disease associated with Interstitial Lung Disease barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Connective Tissue Disease associated with Interstitial Lung Disease Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Connective Tissue Disease associated with Interstitial Lung Disease market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/connective-tissue-disease-associated-with-interstitial-lung-disease-ctd-ild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. CTD-ILD Market Overview at a Glance
4. Methodology of CTD-ILD Epidemiology and Market
5. Executive Summary of CTD-ILD
6. Key Events
7. Disease Background and Overview of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD)
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Therapies
11. Emerging Therapies
12. CTD-ILD: Market Analysis
13. Key Opinion Leaders' Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.